{
    "clinical_study": {
        "@rank": "95597", 
        "arm_group": [
            {
                "arm_group_label": "Intradermal first", 
                "arm_group_type": "Experimental", 
                "description": "Intradermal injection experiment first, followed by subcutaneous injection experiment"
            }, 
            {
                "arm_group_label": "Subcutaneous first", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous injection experiment first, followed by intradermal  injection experiment"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators are doing this research study to find out if the type of needle used to\n      administer them affects the speed with which insulin and glucagon get into the blood. The\n      investigators will compare a traditional insulin needle to an injection device, called the\n      MicronJet, that uses microneedles to deliver medication into the top layer of your skin."
        }, 
        "brief_title": "Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age  18 years or older with clinical type 1 diabetes for at least one year\n\n          -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting\n             insulins including insulin aspart (Novolog), insulin lispro (Humalog), and insulin\n             glulisine (Apidra).\n\n          -  Ability to consume a sufficient amount of carbohydrates over 2-3 hours to cover 5\n             units of rapid acting insulin\n\n          -  Stimulated C-peptide <0.1 nmol/L at 90 minutes after liquid mixed meal tolerance\n             test.\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed consent\n\n          -  Unable to comply with study procedures\n\n          -  Current participation in another diabetes-related clinical trial other than one that\n             is primarily observational in nature. Potential subjects enrolled in trails of\n             passive monitoring equipment, such as continuous glucose monitors (CGMs), are not\n             excluded\n\n          -  Inadequate venous access as determined by study nurse or physician at time of\n             screening\n\n          -  Pregnancy\n\n          -  Hemoglobin less than 13.5 for men and less than 12 for women\n\n          -  History of pheochromocytoma (fractionated metanephrines will be tested in patients\n             with history increasing the risk for a catecholamine secreting tumor to include\n             episodic or treatment refractory hypertension defined as requiring 4 or more\n             medications to achieve normotension, paroxysms of tachycardia, pallor, or headache,\n             or personal or family history of MEN 2A, MEN 2B, neurofibromatosis, or von\n             Hippel-Lindau disease)\n\n          -  History of adverse reaction to glucagon (including allergy) besides nausea and\n             vomiting\n\n          -  History of adrenal disease or tumor\n\n          -  Hypertension (blood pressure > 160/100 mm/Hg at screening or day of study visit\n\n          -  History of allergy to aspirin or any history of aspirin intolerance, including Reye's\n             syndrome, or gastric ulcer or bleeding associated with salicylates.\n\n          -  Blood dyscrasia or bleeding diathesis, such as hemophilia, Von Willebrand's disorder,\n             and idiopathic thrombocytopenic purpura (ITP)\n\n          -  Peptic Ulcer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684956", 
            "org_study_id": "2012P001098"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Intradermal first", 
                    "Subcutaneous first"
                ], 
                "intervention_name": "Intradermal injection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Intradermal first", 
                    "Subcutaneous first"
                ], 
                "intervention_name": "Subcutaneous injection", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "intradermal", 
            "pharmacokinetics", 
            "microneedle", 
            "insulin", 
            "glucagon"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Volunteers With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Steven J Russell, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Aggregate mean difference in tmax between the delivery methods (the insulin and glucagon data will be evaluated separately)", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684956"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Steven J. Russell, MD, PhD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Aggregate mean difference in t1/2max between the methods", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Aggregate mean difference in Cmax between the methods", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Aggregate mean difference in area under the curve (AUC) between methods", 
                "safety_issue": "No"
            }, 
            {
                "measure": "AUC of 0-1 hour (and by subtraction hours 1-5)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "AUC of 0-2 hours (and by subtraction hours 2-5)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to 50% of Total AUC (or said another way, time to 50% exposure)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Fraction of subjects with difference in tmax between the methods of > 25%", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Fraction of \"dry\" injections with no reflux of fluid  from the injection site", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Difference in mean visual analog pain score between the two methods", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Difference in mean visual analog pain score between insulin and glucagon with subcutaneous injection", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Difference in mean visual analog pain score between insulin and glucagon with intradermal injection", 
                "safety_issue": "No"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}